Study at a glance
What is vitamin D toxicity?
This evidence review explains vitamin D toxicity and why one blood result cannot identify every case. Toxicity from excessive vitamin D2 or D3 usually involves disturbed calcium control, especially too much calcium in blood or urine. Symptoms such as nausea, weakness, confusion, thirst and dehydration largely reflect excess calcium. A high vitamin D result alone does not prove that these effects are present.
What can increase the risk of vitamin D toxicity?
Reported cases often involve prolonged very large doses, dosing mistakes or products containing more vitamin D than expected. Other disorders can produce similar calcium problems without a supplement overdose. Some diseases make too much active vitamin D. Rare faults affecting CYP24A1, an enzyme that helps break vitamin D down, can also increase the risk. Kidney function and calcium intake affect interpretation.
Why can vitamin D blood results be misleading?
The usual test measures 25-hydroxyvitamin D, a form that can be converted into active vitamin D. Some diseases can produce excessive active vitamin D even when this usual result is low or ordinary. Conversely, a normal active-vitamin-D result does not exclude toxicity from a large D2 or D3 overdose. Laboratory interference can also affect some measurements.
Does the evidence show one toxic vitamin D level for everyone?
Much of the evidence comes from reported patient cases, accidental exposures and studies of biological processes. It does not establish one level that causes toxicity in everyone. A very high result should not be dismissed because calcium is currently normal. The review supports considering exposure, calcium, hormones and kidney effects together, without assuming supplements caused every case of high calcium.
Read the full article below ↓Vitamin D toxicity is often described as though it were simply the upper end of a vitamin D blood-test scale. Clinically, that is too simple. Classical toxicity from excessive vitamin D₂ or vitamin D₃ intake is characterised by excessive vitamin D exposure accompanied by disturbed calcium physiology, particularly hypercalcaemia or hypercalciuria. Other disorders can produce vitamin D-mediated hypercalcaemia without massive supplement exposure, while a high 25-hydroxyvitamin D [25(OH)D] concentration can occur without symptomatic toxicity. Correct interpretation therefore requires exposure history, calcium, PTH, kidney function, the vitamin D metabolite involved and the possibility of abnormal activation or degradation. For the shorter reader route, see Vitamin D Toxicity: Clinical Contexts, Risk Factors and Misinterpretations: Study Summary.
Toxicity is a clinical and biochemical syndrome, not merely a high number
Reviews of vitamin D toxicity consistently place hypercalcaemia at the centre of the syndrome. Symptoms such as nausea, vomiting, abdominal discomfort, weakness, confusion, polyuria, polydipsia and dehydration largely reflect the effects of elevated calcium rather than a separate set of vitamin-D-specific toxic symptoms.
This distinction matters because laboratory categories and physiological consequences are not interchangeable. A very high 25(OH)D concentration may justify investigation, but it does not by itself prove that a person has clinically significant calcium toxicity. The wider distinction between operational numerical boundaries and physiological meaning is developed in Vitamin D Thresholds vs Targets.
Classical exogenous toxicity usually requires sustained excessive exposure
Vitamin D intoxication from ordinary vitamin D₂ or vitamin D₃ supplements is uncommon at conventional nutritional intakes. The published toxicity literature is dominated by accidental overdosing, formulation or manufacturing errors, inappropriate pharmacological dosing and prolonged use of very large doses. Tebben and colleagues note that intakes above 10,000 IU per day should raise suspicion in an appropriate clinical setting, particularly when hypercalcaemia or hypercalciuria is present, while clinically important intoxication generally involves much larger exposure than standard nutritional use.
The number should not be converted into a guarantee that a particular dose will poison every person. Duration, starting vitamin D status, calcium intake, body distribution and individual metabolism affect the concentration achieved. A dose history is therefore part of the interpretation rather than an optional detail.
Supplement errors are a different risk from ordinary supplementation
Clinical reports of vitamin D intoxication frequently involve circumstances in which the actual exposure differs dramatically from what would be expected from ordinary supplementation. Dosing mistakes can occur when high-dose preparations are taken too frequently, when compounded or manufactured products contain substantially more vitamin D than labelled, or when therapeutic loading regimens continue beyond their intended duration.
This matters for risk communication. Evidence that severe intoxication can follow massive dosing does not establish that ordinary vitamin D use produces the same risk profile. Equally, the rarity of toxicity at ordinary doses does not make prolonged pharmacological dosing automatically safe without regard to calcium physiology, renal function or the indication for treatment.
The high 25(OH)D threshold should not be interpreted as a cliff edge
Clinical reviews often cite concentrations around 150 ng/mL (375 nmol/L) as characteristic of exogenous vitamin D intoxication, while lower values such as 80-100 ng/mL are discussed as levels at which increasing concern or hypervitaminosis becomes relevant. These values are useful orientation points, but the evidence does not establish a concentration at which every person becomes hypercalcaemic.
Tebben and colleagues describe patients with 25(OH)D well above 80 ng/mL who do not have hypercalcaemia or hypercalciuria. Conversely, symptomatic cases usually have concentrations much higher than that. Dietary calcium intake and other physiological variables influence whether a given vitamin D exposure becomes a calcium problem. A high result therefore changes probability and clinical concern rather than acting as a universal toxicity switch.
Hypercalcaemia should not automatically be blamed on vitamin D supplements
Hypercalcaemia has a broad differential diagnosis. Primary hyperparathyroidism and malignancy are major causes, and vitamin D-mediated mechanisms represent only part of that landscape. The presence of a supplement on a medication list does not establish causality. PTH is particularly useful at the first mechanistic split because vitamin D-mediated hypercalcaemia normally suppresses PTH.
When calcium is elevated and PTH is not suppressed, a simple vitamin D intoxication explanation becomes less convincing and other calcium-regulatory mechanisms require consideration. The underlying feedback relationship belongs within Vitamin D and Calcium Physiology.
A low or ordinary 25(OH)D result does not exclude vitamin D-mediated hypercalcaemia
This is one of the most important interpretive traps. Granulomatous diseases and some lymphomas can increase extrarenal conversion of 25(OH)D to 1,25(OH)₂D. The active hormone can therefore become excessive even when the precursor concentration is not dramatically elevated. In such a patient, treating the 25(OH)D number as though it were the whole pathway can obscure the mechanism.
The distinction also explains why active-hormone testing has legitimate specialist uses despite being inappropriate as a routine substitute for 25(OH)D status testing. Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D provides the wider biomarker framework.
Granulomatous disease creates particular supplementation risk
In granulomatous disease, macrophage CYP27B1 can convert available 25(OH)D into calcitriol with less dependence on the regulatory signals that constrain renal synthesis. Increasing the substrate pool can therefore have different consequences from supplementation in a person with ordinary vitamin D metabolism.
This does not mean every patient with sarcoidosis, tuberculosis or another granulomatous disorder will become hypercalcaemic after vitamin D exposure. The evidence supports increased mechanistic caution, not a universal prohibition. Disease activity, existing calcium status, active-hormone production and the amount of supplied substrate all influence risk.
CYP24A1 deficiency can masquerade as excessive vitamin D intake
Another important clinical context is impaired vitamin D degradation. Pathogenic CYP24A1 variants reduce the ability to inactivate 25(OH)D and 1,25(OH)₂D. Affected individuals can develop hypercalcaemia, hypercalciuria, nephrocalcinosis or recurrent kidney stones at exposures that would not ordinarily be considered toxic.
The existing Vitamin D Clearance and Degradation framework is especially relevant here. If a person cannot clear vitamin D metabolites normally, the clinical problem is not adequately described by asking whether the supplement dose exceeded a standard population limit.
This is reinforced by the existing Altered CYP27B1/CYP24A1 Enzyme Activity: Full Evidence Review, which distinguishes reduced degradation from dysregulated production. These mechanisms can converge on hypercalcaemia while requiring different causal interpretation.
Pregnancy can expose an underlying degradation defect
Pregnancy is a useful example of context altering susceptibility. Active vitamin D physiology changes substantially during pregnancy, with increased calcitriol production supporting the mineral demands of the mother and developing fetus. In a person with impaired CYP24A1-mediated degradation, that increased production can expose a previously compensated inability to remove vitamin D metabolites efficiently.
This does not make pregnancy itself a form of vitamin D toxicity. It illustrates a broader principle: an inherited metabolic defect may remain clinically quiet until physiology changes the balance between production and clearance.
Kidney disease changes both risk and consequence
The kidney regulates systemic calcitriol production, contributes to vitamin D catabolism and clears excess calcium through urine. Hypercalcaemia itself can impair renal concentrating ability, promote dehydration and contribute to kidney injury. Hypercalciuria can promote nephrolithiasis and nephrocalcinosis even before severe systemic symptoms develop.
The result is a bidirectional relationship: vitamin D-mediated calcium excess can damage renal function, while impaired renal physiology can alter how safely mineral and vitamin D loads are handled. The organ-level background is developed in Vitamin D and Kidneys.
More vitamin D is not an appropriate response to every low 25(OH)D result
A further misinterpretation occurs when a low 25(OH)D measurement is automatically treated as evidence that more substrate is safe or appropriate. In ordinary nutritional deficiency that reasoning may be straightforward. In a patient with dysregulated extrarenal CYP27B1, however, available 25(OH)D can be rapidly converted to active hormone. In CYP24A1 deficiency, added substrate enters a pathway in which degradation is impaired.
This does not make serum 25(OH)D useless. It shows that an appropriate biomarker must still be interpreted inside the metabolic and clinical context that produced it.
Assays and metabolites can also create interpretive traps
Extremely high 25(OH)D can interfere with some 1,25(OH)₂D assays through cross-reactivity, creating an apparently elevated active-hormone result that is partly analytical rather than physiological. Conversely, a normal 1,25(OH)₂D result does not exclude classical exogenous vitamin D intoxication because renal active-hormone production may be suppressed while very high precursor concentrations drive toxicity through other routes.
This is one reason a toxicity assessment should not be reconstructed from one isolated laboratory value. The metabolite measured, assay method, serum calcium, PTH and exposure history must be interpreted together.
The clearance literature provides a useful mechanistic cross-check
The site’s existing How Vitamin D Clearance Is Physiologically Regulated: Renal Feedback and Tissue-Specific Control: Evidence Synthesis shows why vitamin D exposure cannot be interpreted independently of removal. Renal and intestinal CYP24A1 contribute at different physiological scales, and experimental loss of renal catabolic activity can produce systemic increases in vitamin D metabolites, PTH suppression and hypercalcaemia.
The narrower Renal and Intestinal CYP24A1 Regulation: Full Evidence Review further demonstrates that local intestinal vitamin D activity can increase without reproducing the same circulating phenotype as loss of renal clearance. This matters clinically because “more vitamin D activity” is not one homogeneous state.
What should and should not be called vitamin D toxicity
The term is most precise for clinically important adverse effects caused by excessive vitamin D exposure, particularly when hypercalcaemia or hypercalciuria accompanies a compatible exposure and biochemical pattern. It is less precise when used as a blanket label for every vitamin D-mediated hypercalcaemia syndrome.
Granulomatous calcitriol excess, lymphoma-associated calcitriol production and CYP24A1 deficiency are better described by their mechanisms. They may produce a phenotype resembling vitamin D toxicity, and vitamin D exposure can worsen them, but their initiating pathology is not necessarily excessive supplementation.
Evidence boundaries
The toxicity literature contains unavoidable limitations. Severe deliberate toxicity experiments cannot ethically be performed in humans, so evidence comes largely from clinical series, case reports, mechanistic studies, accidental exposure and the physiology of related disorders. Numerical cut-offs therefore describe patterns of increasing concern rather than experimentally proven universal toxicity boundaries.
The evidence also does not justify dismissing a markedly high 25(OH)D concentration simply because calcium is currently normal. Nor does it justify diagnosing toxicity from the 25(OH)D concentration alone. The most defensible clinical interpretation joins exposure, concentration, calcium physiology, PTH, kidney effects and the underlying metabolic mechanism.
Primary scientific sources and publication details
Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, Płudowski P, Jones G. Vitamin D Toxicity-A Clinical Perspective. Frontiers in Endocrinology. 2018;9:550. PMID: 30294301. PMCID: PMC6158375. DOI: 10.3389/fendo.2018.00550.
Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocrine Reviews. 2016;37(5):521-547. PMID: 27588937. PMCID: PMC5045493. DOI: 10.1210/er.2016-1070.
Galior K, Grebe S, Singh R. Vitamin D Toxicity. Nutrients. 2020. PMCID: PMC7427646.
Schlingmann KP. Vitamin D-dependent Hypercalcemia. Endocrinology and Metabolism Clinics of North America. 2021;50(4):729-742. PMID: 34774244. DOI: 10.1016/j.ecl.2021.08.005.
Tebben PJ, Milliner DS, Horst RL, et al. Hypercalcemia due to CYP24A1 variants in five unrelated patients: diagnostic and clinical considerations. 2025. PMCID: PMC12319318.
Related reading
A case series of hypercalcemia associated with pembrolizumab therapy: evidence for a calcitriol-mediated mechanism
Immune checkpoint inhibitors enhance antitumor immunologic activity by blocking interaction between inhibitory immune checkpoint receptors.
Original paper ↗Read more →Increasing Prevalence of Potential Vitamin D Toxicity and Its Risk Factors in Korea: A Large Population-Based Study
The prevalence of potential toxicity was examined by age, sex, test month, and year.
Original paper ↗Read more →The role of nutritional vitamin D on microinflammation and nutritional status in maintenance hemodialysis patients: a meta-analysis of randomized controlled trials
A total of 617 patients in eight randomized controlled trials were included.
Original paper ↗Read more →Vitamin D Toxicity-A Clinical Perspective
Confusion, apathy, recurrent vomiting, abdominal pain, polyuria, polydipsia, and dehydration are the most often noted clinical symptoms of vitamin D toxicity (VDT; also called vitamin D intoxication or hypervitaminosis D).
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure
Impaired mineral homeostasis and inflammation are hallmarks of chronic kidney disease (CKD), yet the underlying mechanisms of electrolyte regulation during CKD are still unclear.
Original paper ↗Read more →Effect of dietary Ca:P ratio on ionized calcium and calcium homeostasis in cats with early-stage chronic kidney disease
The aim of the study was to compare two renal foods with different Ca:P ratios on manifestation of hypercalcemia and regulation of calcium homeostasis in cats with chronic kidney disease (CKD).
Original paper ↗Read more →Status of vitamin D and parameters of calcium homeostasis in renal transplant recipients in Nepal: a cross sectional study
This study aimed to determine the prevalence of hypovitaminosis D in Nepalese RTRs and interrelations between serum 25-hydroxyvitamin D [25(OH) D] and other biochemical parameters.
Original paper ↗Read more →The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis: clinical practice recommendation from the Pediatric Renal Nutrition Taskforce
Complications of mineral bone disease (MBD) are common and contribute to the high morbidity and mortality seen in children with CKD.
Original paper ↗Read more →Vitamin D-Induced Hypercalcaemia: Mechanisms of Calcium Dysregulation: Full Study
AA full evidence review of how excess vitamin D activity, extrarenal calcitriol production and impaired CYP24A1 clearance can cause hypercalcaemia.
Read more →Association between 25-Hydroxyvitamin D, Parathyroid Hormone, Vitamin D and Calcium Intake, and Bone Density in Healthy Adult Women: A Cross-Sectional Analysis from the D-SOL Study
This cross-sectional analysis aimed to investigate the associations of 25(OH)D and plasma PTH concentrations with bone parameters, and potential confounders, in women living in a high (England) or low (Brazil) latitude country.
Original paper ↗Read more →Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients
Serum calcium, phosphate, alkaline phosphatase,parathyroid hormone, FGF-23, 25(OH)D, 1,25(OH)2D and Fractional excretion of phosphorous were assessed and compared between the two groups, using SPSS software.
Original paper ↗Read more →Positive association between serum calcium-phosphorus ratio and kidney stone prevalence: Analysis of NHANES data (2007 to 2020)
This study utilized data from the 2007 to 2020 National Health and Nutrition Examination Survey (NHANES), including a total of 34,122 participants.
Original paper ↗Read more →The Role of Calcium, 25-Hydroxyvitamin D, and Parathyroid Hormone in Irritable Bowel Syndrome: A Bidirectional Two-Sample Mendelian Randomization Study
Therefore, we aimed to explore the bidirectional causal effects among serum calcium, Vit-D, PTH, and IBS at the genetic level by a two-sample Mendelian randomization (MR) analysis of the datasets from IEU OpenGWAS database.
Original paper ↗Read more →Vitamin D Toxicity: Clinical Contexts, Risk Factors and Misinterpretations: Study Summary
A concise evidence summary of vitamin D toxicity, hypercalcaemia, high-dose exposure, granulomatous disease, CYP24A1 defects and common interpretation errors.
Read more →Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab Bone Mineral Density Response: A Stratified Analysis by Renal Function Category and Prior Treatment History in a Real-World Japanese Cohort
This study investigated whether the renal function category and prior treatment history modified the association between baseline 25OHD and romosozumab BMD response.
Original paper ↗Read more →Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab Bone Mineral Density Response: A Stratified Analysis by Renal Function Category and Prior Treatment History in a Real-World Japanese Cohort
This study investigated whether the renal function category and prior treatment history modified the association between baseline 25OHD and romosozumab BMD response.
Original paper ↗Read more →25(OH)D Concentration in Neonates, Infants, and Toddlers From Poland: Evaluation of Trends During Years 1981 to 2011
The aim of this study was to analyse trends in serum 25-hydroxyvitamin D concentration (25(OH)D) change over the 30 years of operation of a single pediatric diagnostic unit.
Original paper ↗Read more →Analysis of the Efficacy and Safety of Weekly Calcifediol 100 µg in Vitamin D Deficient Patients
This approach aimed to evaluate the generalizability of weekly formulations across different baseline deficiency levels and, consequently, explore the potential for a simplified, standardized dosing regimen in clinical practice.
Original paper ↗Read more →Associations of free, bioavailable and total 25-hydroxyvitamin D with neonatal birth anthropometry and calcium homoeostasis in mother-child pairs in a sunny Mediterranean region
Our objective was to examine the interrelated biodynamics of maternal and neonatal total, free and bioavailable 25(OH)D in maternal: neonatal dyads at birth and their associations with homeostasis and neonatal birth anthropometry.
Original paper ↗Read more →Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal
The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600).
Original paper ↗Read more →Original sources
Vitamin D Toxicity-A Clinical Perspective
Confusion, apathy, recurrent vomiting, abdominal pain, polyuria, polydipsia, and dehydration are the most often noted clinical symptoms of vitamin D toxicity (VDT; also called vitamin D intoxication or hypervitaminosis D).
Publication details
Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, Płudowski P, Jones G. Vitamin D Toxicity-A Clinical Perspective. Frontiers in Endocrinology. 2018;9:550. PMID: 30294301. PMCID: PMC6158375. DOI: 10.3389/fendo.2018.00550.
Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment
Published in Endocrine Reviews (2016).
Publication details
Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocrine Reviews. 2016;37(5):521-547. PMID: 27588937. PMCID: PMC5045493. DOI: 10.1210/er.2016-1070.
Vitamin D Toxicity
Fortification of food products with vitamin D was central to the eradication of rickets in the early parts of the 20th century in the United States.
Publication details
Galior K, Grebe S, Singh R. Vitamin D Toxicity. Nutrients. 2020. PMCID: PMC7427646.
Vitamin D-dependent Hypercalcemia
Published in Endocrinology and Metabolism Clinics of North America (2021).
Publication details
Schlingmann KP. Vitamin D-dependent Hypercalcemia. Endocrinology and Metabolism Clinics of North America. 2021;50(4):729-742. PMID: 34774244. DOI: 10.1016/j.ecl.2021.08.005.
Hypercalcemia due to CYP24A1 variants in five unrelated patients: diagnostic and clinical considerations
Calcitriol-induced hypercalcemia is most frequently caused by granulomatous and inflammatory conditions such as sarcoidosis as well as lymphoma.
Publication details
Tebben PJ, Milliner DS, Horst RL, et al. Hypercalcemia due to CYP24A1 variants in five unrelated patients: diagnostic and clinical considerations. 2025. PMCID: PMC12319318.